<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=us-ascii">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle18
{mso-style-type:personal;
font-family:"Calibri",sans-serif;
color:windowtext;}
span.EmailStyle19
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
font-variant:normal !important;
color:windowtext;
text-transform:none;
text-decoration:none none;
vertical-align:baseline;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:771362927;
mso-list-template-ids:1231580922;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1
{mso-list-id:903489439;
mso-list-template-ids:1639859312;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PA-2D19-2D205.html&d=DwMFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=ofRmrsx-ValQpohJSWKPV4EYwcImj-kt0gudeqvLA9k&s=PHxFY23kQwyZUAyLRj6Zr1-PJPGecN10zQ8XIS3VLBE&e=">ORWH FY19 Administrative Supplement (Admin Supp Clinical Trial Optional): Research on the Health of Women of Understudied, Underrepresented
and Underreported (U3) Populations</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The Office of Research on Women's Health (ORWH) announces the availability of administrative supplements to support interdisciplinary, transdisciplinary and multidisciplinary research focused on the effect
of sex/gender influences at the intersection of several social determinants, including but not limited to: race/ethnicity, socioeconomic status, education, health literacy and other social determinants in human health and illness. This research includes preclinical,
clinical, behavioral and translational studies with the specific purpose to provide Administrative Supplements to active NIH parent grants for one year to address health disparities among women of populations in the US who are understudied, underrepresented
and underreported in biomedical research. The proposed research must address an area specified within Goal 1 and 2 of the new
<a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__orwh.od.nih.gov_about_trans-2Dnih-2Dstrategic-2Dplan-2Dwomens-2Dhealth-2Dresearch&d=DwMFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=ofRmrsx-ValQpohJSWKPV4EYwcImj-kt0gudeqvLA9k&s=fonDQloUhOsEocQEmRQUKFBbJPFywK_yKRNO31bAmEA&e=">
Trans-NIH Strategic Plan for Women's Health Research</a> "Advancing Science for the Health of Women." These goals focus on advancing rigorous research that is relevant to the health of women (Goal 1) and developing methods and leveraging data sources to consider
sex and gender influences that enhance research for the health of women (Goal 2). Projects must include a focus on one or more NIH-designated health disparities populations, which include Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska
Natives, Asian Americans, Native Hawaiians and other Pacific Islanders, socioeconomically disadvantaged populations, underserved rural populations, and sexual and gender minorities (SGM). Combinations of one or more populations is also encouraged, e.g. socioeconomically
disadvantaged sexual and gender minorities.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due April 8, 2019. <span style="color:red">
Med-RA deadline to receive draft documents: March 25.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D19-2D189.html&d=DwMFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=ofRmrsx-ValQpohJSWKPV4EYwcImj-kt0gudeqvLA9k&s=O4ZBjhG6XxhkYtTOSwblquJCk2uo2S5WS_hSdZMk8NU&e=">Pilot Services Research Grants Not Involving Clinical Trials (R34 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The purpose of this funding announcement is to encourage pilot research that is not an immediate precursor to testing a service intervention but is consistent with NIMH priorities for services research.
While NIMH now requires use of an experimental therapeutics model for all intervention studies, there is recognition that some mission-relevant areas of services research do not involve clinical trials. These areas include:<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">1) studies to identify mutable factors that impact access, continuity, utilization, quality, value, outcomes, including disparities in outcomes, or scalability of mental health services, which may serve
as targets in future intervention development<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">2) development and testing of new research tools, measures, or methods<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">3) testing the feasibility of integrating existing data sets to understand factors affecting access, quality or outcomes of care<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">4) pilot work on the learning mental health care system model as a means to enable practical studies of the value and effectiveness of services and treatments<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due March 28, 2019. <span style="color:red">
Med-RA deadline to receive draft documents: March 14.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_rfa-2Dfiles_RFA-2DNS-2D19-2D026.html&d=DwMFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=ofRmrsx-ValQpohJSWKPV4EYwcImj-kt0gudeqvLA9k&s=MZxmXqV7QDR3YIp1jft2FMKwDvZZ9NrLkFww_9pP_ww&e=">Clinical and Biological Measures of TBI-related dementia including Chronic Traumatic Encephalopathy (CTE) (R01 Clinical Trial
Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">This FOA invites investigation of biological and clinical measures of TBI-related progressive neurodegeneration and neurocognitive decline associated with increased risk for dementia and /or traumatic
encephalopathy syndrome (TES) (clinicopathologic diagnostic counterpart to the neuropathological diagnosis of Chronic Traumatic Encephalopathy (CTE)). Investigations should be based on existing, well-characterized populations of patients with a history of
TBI that are enriched for increased risk of cognitive impairment or dementia and can continue to be followed longitudinally; additional subjects may be recruited as appropriate. The overall goal is to advance knowledge of the underlying pathophysiology and
clinical characterization of the chronic effects of TBI that distinguish static-chronic TBI cognitive impairment from those that lead to progressive neurodegeneration associated with TES and dementia. A critical feature of this FOA includes the broad sharing
of clinical, neuroimaging, physiological, and biospecimen data to further advance research in this area<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due April 15, 2019. <span style="color:red">
Med-RA deadline to receive draft documents: April 1.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.floridablue.com_foundation_improve-2Daccess-2Dto-2Dhealth-2Dcare&d=DwMFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=ofRmrsx-ValQpohJSWKPV4EYwcImj-kt0gudeqvLA9k&s=EF2-gCabVzYucWeD7bLQrOBpM4KqLt05d3FGaXP9dsM&e=">Florida Blue Foundation: Innovation in Health Care System</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">The Florida Blue Foundation’s Innovation in the Health Care System focus area aims to connect affordable, non-traditional health services to underserved, underinsured and low-income populations
throughout Florida. The 2019 funding priority for Innovation in the Health Care System is: to support and/or solve health care delivery systems for the underserved, underinsured and low-income populations; in particular seniors
<i>aging in place*</i>. The projects proposed should be designed to increase access and enhance delivery of health care through non-traditional, health services that will improve the overall health of underserved, underinsured and low-income populations; in
particular seniors <i>aging in place</i>, which is defined as the ability to live in one’s own home and community safely while receiving services in their home or at a close-by, accessible community health facility. The Florida Blue Foundation has approximately
$3.5 million for the funding of this program. The Foundation will fund three-year and four-year grants. The average amount per year is from $80,000 up to $100,000 per year. Priority will be given to applicants that include collaborations and partnerships with
other similar organizations in Florida.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due April 24, 2019. <span style="color:red">
Med-RA deadline to receive draft documents: April 10.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__www.floridablue.com_foundation_improve-2Dquality-2Dand-2Dsafety-2Dpatient-2Dcare&d=DwMFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=ofRmrsx-ValQpohJSWKPV4EYwcImj-kt0gudeqvLA9k&s=VaGyWrmsFJyq02s1LE5Ewwj1J4dinTaudu5RpLmhStk&e=">Florida Blue Foundation: Quality of Patient Care</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">The intent of the Quality of Patient Care grant program is to support healthcare education programs and professional development opportunities designed to improve the safety of patient care.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">The 2019 funding priorities for the Quality of Patient Care grant program:
<o:p></o:p></span></p>
<ul style="margin-top:0in" type="disc">
<li class="MsoNormal" style="color:black;mso-list:l0 level1 lfo3"><span style="font-family:Palatino">Health professional programs with a focus on addressing workforce shortages in nursing<o:p></o:p></span></li><li class="MsoNormal" style="color:black;mso-list:l0 level1 lfo3"><span style="font-family:Palatino">Professional development for caregivers who support an aging population that are underserved, underinsured, and/or low-income<o:p></o:p></span></li></ul>
<p class="MsoNormal"><span style="font-family:Palatino;color:black">The Florida Blue Foundation has approximately $1.5 million for the funding of this program. The Foundation will fund three-year grants only. The average funding per year is $80,000 - $100,000.
Priority will be given to applicants that include collaborations and partnerships with other similar nonprofit organizations in Florida.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due April 30, 2019. <span style="color:red">
Med-RA deadline to receive draft documents: April 16.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__docs.google.com_forms_d_1Vqj5ahAPJhoSkfjM-2DuFkXEtbtkkA-5FTdU0dbj3bCTt8g_viewform-3Fedit-5Frequested-3Dtrue&d=DwMFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=ofRmrsx-ValQpohJSWKPV4EYwcImj-kt0gudeqvLA9k&s=PIMUGUUorL_yEsvANsVWncF1A4kakxvW7y82JCl09z4&e=" target="_blank">Tell Every Amazing Lady About Ovarian Cancer Louisa M. McGregor Ovarian
Cancer Foundation (T.E.A.L.): Medical Research Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">T.E.A.L. works to drive medical research, provide survivor support, and promote public awareness and education of the signs, symptoms, and risk factors of ovarian cancer. To that end, the foundation is
accepting applications for its 2019 Medical Research Program. Through the program, grants of up to $40,000 will be awarded to investigators working to advance research on ovarian cancer. To be eligible, applicants must be affiliated with a nonprofit institution
in the United States. Eligible costs include travel, supplies, and the purchase or renting of equipment. Salary and indirect costs are not eligible.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due May 31, 2019. <span style="color:red">
Med-RA deadline to receive draft documents: May 16.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D19-2D202.html&d=DwMFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=ofRmrsx-ValQpohJSWKPV4EYwcImj-kt0gudeqvLA9k&s=3r74R9z97P_6RdPQPilLaBT3EusbJJg-GTxaZYnNNwY&e=" target="_blank">High impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The purpose of the High Impact, Interdisciplinary Science grants program is to support high impact ideas that may lay the foundation for new fields of investigation within the mission of NIDDK. The interdisciplinary
approach encouraged by this FOA is envisioned to generate a research resource and/or foster discovery-based or hypothesis-generating science that can have a significant impact on the broader scientific community. This FOA seeks novel approaches in areas that
address specific knowledge gaps, scientific opportunities, new technologies, data generation, or research methods that will advance the area in significant ways designed to accelerate scientific progress in the understanding, treatment, and prevention of diseases
within the mission of NIDDK.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Due May 30, 2019; October 31, 2019; June 2, 2020; November 3, 2020; June 1, 2021; and November 2, 2021.
<span style="color:red">Med-RA deadline to receive draft documents for May submission: May 15.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="Innovative%20Mental%20Health%20Services%20Research%20Not%20Involving%20Clinical%20Trials%20%20(R01)">Innovative Mental Health Services Research Not Involving Clinical Trials (R01)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The purpose of this funding announcement is to encourage innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest
number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial R01-level projects that address NIMH strategic priorities for mental health services research (see
<a href="https://urldefense.proofpoint.com/v2/url?u=http-3A__www.nimh.nih.gov_about_strategic-2Dplanning-2Dreports_strategic-2Dresearch-2Dpriorities_srp-2Dobjective-2D4_index.shtml&d=DwMFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=ofRmrsx-ValQpohJSWKPV4EYwcImj-kt0gudeqvLA9k&s=ru9l1dkAdJEQv4aDbcFGNaBiw6AbVMNxEsiglGmk-C4&e=">
http://www.nimh.nih.gov/about/strategic-planning-reports/strategic-research-priorities/srp-objective-4/index.shtml</a>).<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">Proposed research should seek to:<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">1) Identify mutable factors that impact access, continuity, utilization, quality, value, and outcomes, including disparities in outcomes, or scalability of mental health services in the United States,
which may serve as targets in future service delivery intervention development;<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">2) Develop and test new research tools, technologies, measures, or methods and statistical approaches to study these issues;<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">3) Integrate and analyze large data sets to understand factors affecting mental health services outcomes using sophisticated computational and predictive analytic approaches;<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">4) Wherever possible, leverage existing infrastructure and partnerships to accomplish these goals.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Standard dates apply. Expires September 8, 2020.
<span style="color:red">Med-RA deadline to receive draft documents for new June 5 R01 submission: May 21.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Microbial-based Cancer Therapy -Bugs as Drugs (R21 / R01 Clinical Trial Not Allowed)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_par-2D19-2D194.html&d=DwMFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=ofRmrsx-ValQpohJSWKPV4EYwcImj-kt0gudeqvLA9k&s=iC1C87tVHj0s3e_ewE8txrz1-6bsBeABceOl8rQSHoA&e=" target="_blank">R21</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__grants.nih.gov_grants_guide_pa-2Dfiles_PAR-2D19-2D193.html&d=DwMFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=ofRmrsx-ValQpohJSWKPV4EYwcImj-kt0gudeqvLA9k&s=AKTZG3U47gD87eRUSowDzzrlcqckGfrSy1UMPDg6Ra8&e=" target="_blank">R01</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family:Palatino">The overall purpose of these funding opportunity announcements (FOAs) is to stimulate the development of novel microbial-based cancer therapies, especially for conditions where conventional cancer therapies
are inadequate, such as poorly vascularized, hypoxic, solid tumors, dormant or slowly dividing cells resistant to current interventions, and brain tumors. Utilizing bacteria, archaebacteria, bacteriophages and other non-virus microorganisms, this initiative
will support research projects designed to study the underlying mechanisms of the complex interactions between microorganisms, tumor, and immune system. These FOAs also aim to support research into the use of microorganisms as delivery vehicles for cancer
treatment and to complement or synergize with current therapies. These FOAs will accept basic mechanistic and preclinical studies in cell culture and animal models in accordance with the state of the science. Applicants applying to these FOAs are encouraged
to address both the microbial and the tumor aspects of microbial-based cancer therapy.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino">Standard dates apply. Expires May 8, 2022.
<span style="color:red">Med-RA deadline to receive draft documents for new June 5 R01 submission: May 21. Med-RA deadline to receive draft documents for new July 16 R21 submission: July 1.</span></span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:11.0pt"><o:p> </o:p></span></p>
</div>
</body>
</html>